NASDAQ:BDTX

Black Diamond Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy BDTX

*Your capital is at risk

$1.69

-0.0250 (-1.46%)

At Close: Jul 31, 2026

Black Diamond Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -77.13. In total, the insiders bought 5.58M and sold 12.01M BDTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-77.13
● Buy	5.58M shares
● Sell	12.01M shares
84% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Jun 26, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -77.13. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (84% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 19, 2025 Sell	Common Stock S-Sale	Biotech Growth N V 10 Percent Owner	10% Owner	400 000 Value: $837.2K
Mar 19, 2025 Sell	Common Stock S-Sale	Biotech Growth N V 10 Percent Owner	10% Owner	2 000 000 Value: $4.00M
Mar 19, 2025 Sell	Common Stock S-Sale	Biotech Growth N V 10 Percent Owner	10% Owner	1 000 000 Value: $2.31M
Mar 19, 2025 Sell	Common Stock S-Sale	Biotech Growth N V 10 Percent Owner	10% Owner	300 000 Value: $582.9K
Mar 19, 2025 Sell	Common Stock S-Sale	Biotech Growth N V 10 Percent Owner	10% Owner	1 000 000 Value: $2.07M
Jan 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Velleca Mark A. President & CEO	CEO / President	500 000 Value: $1.26M
Jan 30, 2025 Buy	Common Stock A-Award	Velleca Mark A. President & CEO	CEO / President	75 000 Value: $189.0K
Jan 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Yurasov Sergey Chief Medical Officer	Officer	200 000 Value: $504.0K
Jan 30, 2025 Buy	Common Stock A-Award	Yurasov Sergey Chief Medical Officer	Officer	75 000 Value: $189.0K
Jan 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Buck Elizabeth Chief Scientific Officer	Officer	175 000 Value: $441.0K
Jan 30, 2025 Buy	Common Stock A-Award	Buck Elizabeth Chief Scientific Officer	Officer	75 000 Value: $189.0K
Jan 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Jones Erika See Remarks	Officer	125 000 Value: $315.0K
Jan 30, 2025 Buy	Common Stock A-Award	Jones Erika See Remarks	Officer	75 000 Value: $189.0K
Jan 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Hatzis-schoch Brent See Remarks	Officer	175 000 Value: $441.0K
Jan 30, 2025 Buy	Common Stock A-Award	Hatzis-schoch Brent See Remarks	Officer	75 000 Value: $189.0K
Jan 30, 2025 Buy	Common Stock A-Award	Hatzis-schoch Brent See Remarks	Officer	75 000 Value: $189.0K
Jan 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Hatzis-schoch Brent See Remarks	Officer	175 000 Value: $441.0K
Jan 30, 2025 Buy	Common Stock A-Award	Jones Erika See Remarks	Officer	75 000 Value: $189.0K
Jan 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Jones Erika See Remarks	Officer	125 000 Value: $315.0K
Jan 30, 2025 Buy	Common Stock A-Award	Buck Elizabeth Chief Scientific Officer	Officer	75 000 Value: $189.0K
Jan 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Buck Elizabeth Chief Scientific Officer	Officer	175 000 Value: $441.0K
Jan 30, 2025 Buy	Common Stock A-Award	Yurasov Sergey Chief Medical Officer	Officer	75 000 Value: $189.0K
Jan 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Yurasov Sergey Chief Medical Officer	Officer	200 000 Value: $504.0K
Jan 30, 2025 Buy	Common Stock A-Award	Velleca Mark A. President & CEO	CEO / President	75 000 Value: $189.0K
Jan 30, 2025 Buy	Stock Option (Right to Buy) A-Award	Velleca Mark A. President & CEO	CEO / President	500 000 Value: $1.26M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BLACK DIAMOND THERAPEUTICS INC.

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penet...

Read Full Profile Here